DRUGS CONTRADICTING FATTY ACID AND MYCOLIC ACID SYNTHESIS

与脂肪酸和分枝菌酸合成相矛盾的药物

• 批准号: 6340739
• 负责人: Patrick Joseph Brennan
• 金额: $ 11.4万
• 依托单位: COLORADO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2001-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6340739
• 关键词: Mycobacterium tuberculosis; antitubercular agents; bacterial antigens; bacterial proteins; cell wall; combinatorial chemistry; drug discovery /isolation; enzyme activity; expression cloning; fatty acid biosynthesis; fatty acid synthase; hydroxy fatty acid; microorganism metabolism; protein structure function; thiourea

Project 1 focuses on fatty acid synthesis and mycolic acid synthesis and cell wall deposition as the shared theme between CSU and SmithKline Beecham (SB). A primary purpose of the Project is to facilitate the involvement of SB in the tuberculosis drug discovery initiative, and these themes are in conformity with SB's emphasis on fatty acid synthesis in several Gram-positive bacteria as the target for drug discovery. Specific Aim 1 at SB addresses the application of high throughput screens (HTS), cytotoxicity, and efficacy studies and medicinal chemistry to the SKF series of SM compounds, some of which show exceptional promise. Also, the characteristic FAS I, FAS II and mycolylsynthase of M. tuberculosis will be incorporated into SB's mainstream three-phase anti-infectives drug discovery program. Specific Aim 2 (at CSU) continues with the surprising observation that the primary effect of isoxyl is probably not on mycolic acid but on oleic acid (and, hence, tuberculostearic acid) synthesis and, hence the desaturases (DesA1/A2) are the primary targets of a host of thioureas. Specific Aim 3 (at CSU and Texas A&M) addresses mycolic acid transfer through membrane and deposition in metabolic end-products, from genetic, structural and enzymatic-assay perspectives prior to the application of full-scale HTS.

项目1的重点是脂肪酸合成、霉菌酸合成和细胞壁沉积，这是CSU和SmithKline Beecham （SB）的共同主题。该项目的一个主要目的是促进SB参与结核病药物发现倡议，这些主题与SB强调几种革兰氏阳性细菌的脂肪酸合成作为药物发现的目标是一致的。针对SB的特异性Aim 1涉及SKF系列SM化合物的高通量筛选（HTS）、细胞毒性、疗效研究和药物化学的应用，其中一些化合物显示出非凡的前景。此外，结核分枝杆菌特有的FAS I、FAS II和mycolylsynthase将被纳入SB的主流三期抗感染药物发现计划。特定目标2（在CSU）继续令人惊讶的观察，异氧基的主要作用可能不是对霉菌酸，而是对油酸（因此，结核硬脂酸）的合成，因此，去饱和酶（DesA1/A2）是硫脲宿主的主要目标。具体目标3（在CSU和Texas A&M）在全面应用HTS之前，从遗传，结构和酶分析的角度解决霉菌酸通过膜转移和代谢最终产物沉积的问题。